The UK Medical Cannabis Market: Growth, Diversification and Opportunities

In recent years, the UK medical cannabis market has evolved dramatically, becoming one of the most dynamic in Europe. According to a recent report from Cannamonitor, The growth of private prescriptions and product diversity continues to accelerate. This article analyzes the key dynamics shaping this market, from the rise of diversified products to regulatory challenges, exploring how the sector could continue to evolve in the years ahead.

Dazzling growth since legalization

Since the Legalization of medical cannabis in the UK in 2018, the market has experienced impressive growth. The number of products prescribed has risen from just 278 in 2019 to over 124,000 in 2022, with a forecast of over 350,000 products prescribed in 2023. Compared with France, this market dynamic has been largely driven by private players, as the NHS remains in the background and issued only a few prescriptions via the public system. In response to this lack of support, private clinics have emerged to offer patients an alternative, thus promoting wider, albeit costly, access to medical cannabis treatments.

This private access model, along with a liberal approach to the formats of available products, has led to a rapid expansion of the range of products on offer. Flowers, oils, vapes and capsules now offer a wide range of choices for prescribers and patients alike, enabling them to personalize their treatments.

However, this growth also raises questions on equity of access and the high cost of treatment for serious pathologies. Although competition has brought prices down and encouraged initiatives to improve access for vulnerable populations, major challenges remain.

Medical cannabis in the UK: number of products prescribed

Product diversity: between the dominance of flowers and new options

Although two hundred fairly diverse products are available, the UK market remains dominated by flower prescriptions, which accounted for 79 % of products supplied in 2023, with a marked preference for those with a high THC content.

The popularity of flowers contrasts with that of oils, which grew in absolute terms, but lost market share by 2023, now accounting for 20 % of prescriptions. More innovative formats, such as capsules and vapes, are still struggling to capture a significant share of the market.

High-THC flowers continue to gain market share, but demand for a more diverse range of products could emerge as patients and prescribers become more educated. At the same time, interest in CBD-balanced products and non-inhaled formats, such as oils, capsules or lozenges, could grow, offering patients a wider variety of options for their therapeutic relief.

Medical cannabis in the UK: product types

Increasingly competitive supply between Europe and Canada

The UK market is mainly supplied by European imports, with around 75 % of the total. products supplied to patients from countries such as Portugal, Spain, Northern Macedonia and Denmark. However, Commonwealth countries such as Canada, Australia and South Africa also play an important role.

The market share of Canadian products doubled between 2022 and 2023, particularly in the higher THC flower segment, where Canadian products accounted for 56 % of sales. However, in 2024, Portuguese and Macedonian growers responded to this trend with the introduction of varieties containing more than 24% THC. Also in 2024, the first cultivated products in the UK have been launched on the market.

Competition between more than 30 producers creates a highly competitive market environment, which could influence the diversity of products. products available for UK patients.

Market concentration around popular strains

The UK medical cannabis market is highly concentrated around a few popular flowering strains. Of the more than 100 strains available on prescription, the top 10 varieties account for 60 % of the market, while the 20 most popular varieties accounted for 80% of demand. Among these, indica-dominant hybrids such as the Gorilla Glue #4 and GSC (Girl Scout Cookies) are among the most popular with patients.

This concentration illustrates a marked preference for well-known varieties, often chosen for their rapid therapeutic effects and high THC content.

Medical cannabis in the UK: «flower» products»

Market outlook: evolving patient needs

While demand for THC-rich flowers continues to grow, the UK market may, in future, favour a more diversified, patient-oriented approach that is not limited to THC content. As the market evolves and patients become more informed, it is likely that features such as terpene profiles, the specific effects of different strains and alternative consumption methods will gain in popularity.

For suppliers, this represents an opportunity to develop innovative, well-differentiated products, adapted to the varied needs of patients, and to position themselves in a market undergoing rapid transformation. The UK, with its growing demand for products complying with good manufacturing practice standards (GMP), remains an attractive destination for suppliers from all over the world, although challenges of quality and accessibility persist.

But the UK's booming medical cannabis market could soon face regulatory challenges. The boom in prescriptions for products with high THC content raises concerns about a shift from medical to quasi-recreational use, particularly among a predominantly male and younger audience. In this context, health authorities could consider imposing plain packaging to limit visual appeal, as well as additional restrictions on marketing and advertising to prevent the normalization of cannabis use in younger demographic segments.

Driven by growing demand and an ever-expanding range of products, the market for medical cannabis in the UK is at a turning point. Growth prospects remain high, and for companies that prioritize innovation, quality and accessibility, the UK market offers solid opportunities in a rapidly changing environment. With the support of a balanced regulatory framework, the market could continue its evolution towards a sustainable industry focused on patient well-being.